Viking Therapeutics Earnings Reports

Viking Therapeutics posted a net loss in Q1 2025 with no revenues recorded, driven by increased R&D and G&A expenses. The company highlighted significant progress in its VK2735 development programs and maintained a robust cash balance of $852 million.

Viking Therapeutics reported a net loss of $35.4 million, or $0.32 per share, for the fourth quarter of 2024. The company's research and development expenses were $31.0 million, and general and administrative expenses were $15.3 million. Viking ended the year with a strong cash position of $903 million.

Viking Therapeutics reported a net loss of $24.9 million, or $0.22 per share, for the third quarter ended September 30, 2024. The company's cash position remained strong with $930 million in cash and equivalents. The company is advancing its clinical programs, including VK2735 and VK2809, with upcoming presentations at scientific conferences.

Viking Therapeutics reported a net loss of $22.3 million, or $0.20 per share, for the three months ended June 30, 2024. The company's cash, cash equivalents, and short-term investments totaled $942 million as of June 30, 2024. The company is advancing VK2735 to Phase 3 for obesity and plans to initiate an oral VK2735 Phase 2 study in obesity in 4Q24.

Viking Therapeutics reported positive topline results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity, and encouraging initial data from a Phase 1 study of oral tablet formulation of this compound. The company completed a public offering of common stock, raising approximately $630 million of gross proceeds.

Viking Therapeutics reported a net loss of $24.6 million, or $0.25 per share, for the fourth quarter ended December 31, 2023. The company's research and development expenses were $20.5 million, and general and administrative expenses were $8.8 million. As of December 31, 2023, Viking held approximately $362 million in cash, cash equivalents, and marketable securities.

Viking Therapeutics reported a net loss of $22.5 million, or $0.23 per share, for the third quarter ended September 30, 2023. The company's cash position remained strong at $376 million. Clinical trials for VK2735 and VK2809 are progressing, with results expected in 1H24.

Viking Therapeutics reported positive top-line results from its Phase 2b VOYAGE study of VK2809 in NASH patients, showing up to 55% median liver fat reduction. A Phase 2 study of VK2735 in obesity is planned for 3Q23, and the company anticipates reporting histology data from VOYAGE in the first half of 2024. The company's cash position at the end of the quarter was $393 million.

Viking Therapeutics reported a net loss of $19.5 million, or $0.25 per share, for the first quarter ended March 31, 2023. The company's research and development expenses were $11.0 million, while general and administrative expenses were $9.5 million. Viking ended the quarter with $135.7 million in cash, cash equivalents and short-term investments.

Viking Therapeutics reported a net loss of $19.6 million, or $0.26 per share, for the three months ended December 31, 2022. The company ended the quarter with a strong cash position of approximately $155 million, providing an operating runway that extends beyond the key milestones for its clinical programs.

Viking Therapeutics reported a net loss of $15.8 million, or $0.21 per share, for the third quarter ended September 30, 2022. The company ended the quarter with $155 million in cash and is positioned to announce data from three clinical programs in 2023.

Viking Therapeutics reported a net loss of $17.4 million, or $0.23 per share, for the second quarter ended June 30, 2022. The company ended the quarter with $169 million in cash, cash equivalents and short-term investments.

Viking Therapeutics reported a net loss of $16.1 million, or $0.21 per share, for the first quarter ended March 31, 2022. The company's cash balance was $185 million, providing a runway through multiple clinical catalysts.

Viking Therapeutics reported a net loss of $12.4 million, or $0.16 per share, for the fourth quarter ended December 31, 2021. The company's research and development expenses were $9.8 million, and general and administrative expenses were $2.7 million. The company ended the quarter with $202.1 million in cash, cash equivalents and short-term investments.

Viking Therapeutics reported a net loss of $13.2 million, or $0.17 per share, for the three months ended September 30, 2021. The company ended the quarter with approximately $216 million in cash, cash equivalents and short-term investments.

Viking Therapeutics reported a net loss of $15.4 million, or $0.20 per share, for the second quarter ended June 30, 2021. The company's cash, cash equivalents, and short-term investments totaled $228.3 million as of June 30, 2021, providing sufficient capital to advance clinical programs into late-stage development.

Viking Therapeutics reported a net loss of $14.0 million, or $0.19 per share, for the first quarter ended March 31, 2021. The company's cash, cash equivalents, and short-term investments totaled $241.7 million at the end of the quarter.

Viking Therapeutics reported a net loss of $10.9 million, or $0.15 per share, for the three months ended December 31, 2020. The company's cash, cash equivalents and short-term investments totaled $248.4 million.

Viking Therapeutics reported a net loss of $9.3 million, or $0.13 per share, for the third quarter ended September 30, 2020. The company's balance sheet remains strong with $255.3 million in cash, cash equivalents and short-term investments.

Viking Therapeutics reported a net loss of $9.6 million, or $0.13 per share, for the second quarter ended June 30, 2020. The company's cash balance remains strong, with approximately $263 million in cash, cash equivalents and short-term investments as of June 30, 2020.

Viking Therapeutics reported a net loss of $9.7 million, or $0.13 per share, for the first quarter ended March 31, 2020. The company ended the quarter with $269.2 million in cash, cash equivalents and short-term investments.